C57BL/6NCya-Cd274em1flox/Cya
Common Name
Cd274-flox
Product ID
S-CKO-12550
Backgroud
C57BL/6NCya
Strain ID
CKOCMP-60533-Cd274-B6N-VA
Status
When using this mouse strain in a publication, please cite “Cd274-flox Mouse (Catalog S-CKO-12550) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Cd274-flox
Strain ID
CKOCMP-60533-Cd274-B6N-VA
Gene Name
Product ID
S-CKO-12550
Gene Alias
B7h1, Pdl1, Pdcd1l1, Pdcd1lg1, A530045L16Rik
Background
C57BL/6NCya
Gene Full Name
CD274 antigen
Modification
Conditional knockout
NCBI ID
Phenotype
Chromosome
Chr 19 (Mouse)
Application
--
Datasheet
Strain Description
Ensembl Transcript ID
ENSMUST00000016640
NCBI Transcript ID
NM_021893
Target Region
Exon 2
Size of Effective Region
~0.6 kb
Overview of Gene Research
Cd274, also known as Programmed cell death ligand 1 (PD-L1), is an essential immune checkpoint protein. It binds to programmed death 1 (PD-1) on T-lymphocytes. The binding inhibits T cell proliferation and activity, leading to tumor immunosuppression, allowing cancer cells to escape immune surveillance [3].
A large meta-analysis of 250 eligible studies including 57322 patients showed that CD274 (PD-L1) overexpression was associated with worse overall survival in non-small cell lung cancer, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, and colorectal cancer, suggesting it could be a potential biomarker for multiple types of cancers [1]. In colorectal cancer, CD274 on immune cells was associated with good prognosis, while its expression on tumour cells had heterogenous outcomes and didn't meet the requirements of a prognostic marker [2].
Baicalein, a monomer of traditional Chinese medicine, can target CD274 and induce its autophagic-lysosomal degradation, which inhibits tumor development by boosting T-cell-mediated antitumor immunity [4].
In conclusion, Cd274 plays a crucial role in cancer immune evasion through its interaction with PD-1 on T-lymphocytes. Studies on Cd274 have implications for understanding cancer prognosis and developing immunotherapies. The identification of substances like baicalein that can degrade CD274 provides potential new strategies for cancer treatment.
References：
1. Park, Ji Hyun, Luchini, Claudio, Nottegar, Alessia, Lim, Beom Jin, Smith, Lee. 2023. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis. In Journal of clinical pathology, 76, 450-456. doi:10.1136/jcp-2023-208848. https://pubmed.ncbi.nlm.nih.gov/37130750/
2. Alexander, Peter G, McMillan, Donald C, Park, James H. 2020. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. In Critical reviews in oncology/hematology, 157, 103147. doi:10.1016/j.critrevonc.2020.103147. https://pubmed.ncbi.nlm.nih.gov/33278675/
3. Gou, Qian, Dong, Chen, Xu, Huihui, Shi, Juanjuan, Hou, Yongzhong. 2020. PD-L1 degradation pathway and immunotherapy for cancer. In Cell death & disease, 11, 955. doi:10.1038/s41419-020-03140-2. https://pubmed.ncbi.nlm.nih.gov/33159034/
4. Hao, Bingjie, Lin, Shumeng, Liu, Haipeng, Xia, Qing, Fan, Lihong. 2024. Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity. In Autophagy, 21, 917-933. doi:10.1080/15548627.2024.2439657. https://pubmed.ncbi.nlm.nih.gov/39710370/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
